ALAB earnings analysis
What we found in ALAB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Astera Labs delivered Q2 revenue of $392.4 million, up 104% year over year and 27% sequentially, while GAAP operating income rose 124% to $89.2 million and reported EPS was $0.80. The principal trade-off was gross-margin compression to 73.3%, down 250 basis points year over year, as hardware-module mix increased. Operating cash flow was $162.3 million for the first half, but receivables and inventory created a $184.0 million working-capital outflow; liquidity nevertheless stood at $1.3 billion. The 10-Q provided no numerical earnings outlook, although management expects existing liquidity to support operations for at least the next 12 months and beyond.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue more than doubled year over year
- Q2 revenue rose $200.5 million, or 104% year over year, to $392.4 million, and increased $84.4 million, or 27%, from Q1 2026 revenue of $308.0 million. Management attributed growth to higher Aries, Scorpio and Taurus shipments and a richer mix of hardware modules and Scorpio products.
- Operating leverage improved
- GAAP operating income increased 124% year over year to $89.2 million from $39.8 million. Operating margin was 22.7%, up 2.0 percentage points from 20.7% a year earlier and 2.6 points from 20.1% in Q1 2026.
- EPS and net income accelerated
- Reported diluted EPS was $0.80, versus $0.44 in Q1 2026 and $0.29 in Q2 2025. Net income increased 199% year over year to $153.1 million from $51.2 million, aided by a $50.3 million income-tax benefit.
- Operating cash flow and liquidity remain strong
- Six-month operating cash flow increased $16.4 million to $162.3 million, compared with $145.9 million in the prior-year period. Liquidity totaled $1.3 billion in cash, cash equivalents and marketable securities at June 30, 2026.
- R&D investment keeps pace with demand
- Management invested for growth: Q2 R&D expense rose $69.2 million, or 104%, to $135.9 million, while R&D remained 35% of revenue. The increase included $32.7 million more personnel expense, $18.6 million more stock compensation, and an 118% increase in R&D headcount.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Product mix drove gross-margin compression
- Gross margin contracted 250 basis points year over year to 73.3% from 75.8%, and declined 300 basis points sequentially from 76.3% in Q1 2026. Management cited a greater mix of lower-margin hardware modules and the impact of warrants.
- Receivables and inventory consumed cash
- Working-capital needs absorbed cash: six-month operating assets and liabilities produced a $184.0 million unfavorable change, including a $124.0 million accounts-receivable change and a $38.6 million inventory change. Inventory was built to support anticipated demand, while receivables reflected higher sales and payment timing.
- Investment and acquisition cash outflows rose
- Net investing cash use rose to $225.6 million in the first six months of 2026 from $67.6 million a year earlier, including a $21.5 million increase in property-and-equipment purchases and a $69.2 million increase in acquisition-related payments. Free cash flow was not disclosed in the filing.
- No material risk-factor updates
- The company reported no material changes to risk factors from its February 20, 2026 Form 10-K. Nonetheless, it states that if outside capital is needed and cannot be raised on reasonable terms, results and financial condition could be adversely affected; current liquidity was $1.3 billion.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.8
- Gross margin
- 73.3%
- Operating margin
- 22.7%
What they said about what is next.
The 10-Q contains no quantitative revenue or EPS outlook. Management stated that $1.3 billion of cash, cash equivalents and marketable securities at June 30, 2026 is expected to fund operations for at least the next 12 months and beyond.
The filing reads better than the one before it.
What came before.
- 10-Q · May 5, 2026
- Astera Labs reported Q1 2026 results with revenue of $308.4 million, a 93% year-over-year increase and a 14% increase from the prior quarter. EPS exceeded expectations at $0.61, up from $0.18 in Q1 2025, indicating…
- 10-K · February 20, 2026
- Astera Labs describes an "Intelligent Connectivity Platform" of four product families (Aries, Taurus, Leo, Scorpio) plus the COSMOS software suite targeting hyperscalers and AI/cloud infrastructure. Revenue accelerated…
- 10-Q · November 5, 2024
- Astera Labs reported Q3 revenue of $113,086,000 (three months ended September 30, 2024), up sharply from $36,928,000 in Q3 2023, while gross margin remained high at ~77.7%. The company generated positive operating cash…
- 10-Q · August 7, 2024
- Astera Labs reported Q2 revenue of $76.85M, a large YoY increase from $10.69M and a sequential increase from Q1 (Q1 implied revenue $65.26M). Gross margin remained strong at 77.9%, while the company remains unprofitable…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALAB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever